רווח נקי למניה (EPS TTM): VYNE Therapeutics Inc (VYNE)

VYNE Therapeutics (VYNE) is implementing software robots for clinical data analysis and developing highly scalable inhibitors for autoimmune skin pathologies. This daily price chart from GURU.Markets showing the current rolling annual EPS indicates that -26.89 represents the latest level. However, VYNE Therapeutics (VYNE) faces intense pressure from pharma behemoths engaged in an aggressive battle for patient attention.
פילוחים אנליטיים ודוחות נתונים של חברת VYNE Therapeutics (VYNE)

This metric is calculated by dividing the total annual net income by the total number of outstanding shares. It measures real capital efficiency, signaling business stagnation when values remain excessively stable. For VYNE Therapeutics (VYNE), this balance is critical, as the development of unique molecule delivery systems requires massive investments. GURU.Markets analysts recommend using the rolling trailing twelve-month earnings per share to identify hidden financial risks. The price action on this chart determines the viability of the company's innovative model.